 Lipoprotein Lpa has been associated with increased risk of cardiovascular disease. Niacin has been shown to lower Lpa in patients with normal or moderately elevated levels. However, there are few studies assessing the effectiveness of niacin in Lpa levels above 30 mgdl. In addition, most studies investigating the effectiveness of niacin have only included small numbers of patients. Also, Lpa was only assessed as a secondary endpoint. The aim of the present study was, therefore, to evaluate whether Niacin is effective compared to placebo in the reduction of an elevated Lpa. 